This study—while it failed its primary endpoint in the broad study population encompassing patients with early-stage and late-stage tendinopathy—revealed significant and clinically relevant improvement of tendinopathic symptoms by IL-17A blockade in the patient population with early-stage moderate-to-severe rotator cuff tendinopathy as identified by prespecified post hoc analysis.16 Here, IL17A is linked to disease of the tendon.